NASDAQ:GTBP GT Biopharma Q2 2026 Earnings Report $0.34 -0.01 (-3.01%) Closing price 07/23/2026 04:00 PM EasternExtended Trading$0.33 -0.01 (-1.85%) As of 04:11 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. ProfileEarnings HistoryForecast GT Biopharma EPS ResultsActual EPSN/AConsensus EPS -$0.08Beat/MissN/AOne Year Ago EPSN/AGT Biopharma Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AGT Biopharma Announcement DetailsQuarterQ2 2026Date8/13/2026TimeBefore Market OpensConference Call DateFriday, August 14, 2026Conference Call Time9:30AM ETConference Call ResourcesEarnings HistoryCompany Profile GT Biopharma Earnings HeadlinesA Clinical-Stage Cancer Company Is Putting AI to Work at the Bench, Designing Its Next Generation of Tumor-Targeting DrugsJuly 6, 2026 | tmcnet.comA Clinical-Stage Cancer Company Is Putting AI to Work Designing Its Next Generation of Tumor-Targeting DrugsJuly 1, 2026 | theglobeandmail.comThis tiny piece of glass could be bigger than GPUsJensen Huang says AI can't scale without it. Google Ventures calls it the future of AI compute. Sequoia Capital - the firm behind Anthropic and OpenAI - calls it a 'holy grail.' It's smaller than a fingertip and made of glass. Wall Street insider Jason Bodner - who called Nvidia at $4.50 - believes this 'light-speed' device could be bigger for AI than GPUs and is about to launch a new wave of winners. He's sharing his number one stock pick tied to it at no cost. | Brownstone Research (Ad)A Third Cancer Drug Just Entered the Clinic at an Under-$20-Million CompanyJune 23, 2026 | theglobeandmail.comThree Cancer Drugs Have Reached the Clinic: Inside GT Biopharma's TriKE BetJune 8, 2026 | markets.businessinsider.comThree Cancer Drugs Have Reached the Clinic: Inside GT Biopharma’s TriKE BetJune 8, 2026 | financialpost.comFSee More GT Biopharma Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like GT Biopharma? Sign up for Earnings360's daily newsletter to receive timely earnings updates on GT Biopharma and other key companies, straight to your email. Email Address About GT BiopharmaGT Biopharma (NASDAQ:GTBP) is a clinical-stage biopharmaceutical company dedicated to developing novel immuno-oncology therapies utilizing its proprietary Tri-specific NK cell engager (TriKE) platform. This technology is designed to harness and enhance the body’s natural killer (NK) cells by simultaneously binding tumor antigens and interleukin-15 (IL-15), stimulating NK cell proliferation and targeted cytotoxicity. By focusing on NK cell engagement rather than T-cell activation, the company aims to offer therapies with potentially improved safety profiles and reduced immune-related adverse events. The company’s lead candidate, GTB-3550, is currently in clinical trials for hematologic malignancies such as acute myeloid leukemia (AML), chronic lymphocytic leukemia (CLL) and myelodysplastic syndromes (MDS). Beyond GTB-3550, GT Biopharma is advancing a pipeline of preclinical TriKE constructs aimed at both hematologic and solid tumors, as well as exploring applications in infectious diseases. The modular nature of the TriKE platform enables rapid development of new molecules targeting diverse antigens, supporting strategic combination therapies and expansion into multiple oncology indications. Founded in 2015 with technology originally licensed from the National Institutes of Health, GT Biopharma is headquartered in Tempe, Arizona, and conducts research and development operations in the United States. The company collaborates with leading academic institutions and global clinical sites to advance its pipeline. Under the leadership of President and CEO Scott K. Koenig, GT Biopharma continues to pursue its mission of delivering next-generation cell-engaging therapies to improve outcomes for patients with cancer and beyond.View GT Biopharma ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles AMD’s $5 Billion Anthropic Deal Could Redraw the AI Chip BattleAlphabet Crushed Earnings, But One Number Spooked the MarketPremium Retail’s Stress Test Is Separating Winners From LosersGE Vernova Just Sent a Mixed AI Signal to InvestorsOtis Took Another Guidance Cut—But the Story Isn't OverPhilip Morris Trimmed Guidance, But Its Growth Story Looks UnshakenD-Wave Quantum or a Quantum ETF: Which Is the Better Bet? Upcoming Earnings Baker Hughes (7/26/2026)Nucor (7/27/2026)Cadence Design Systems (7/27/2026)Coca Cola Femsa (7/27/2026)Welltower (7/27/2026)Astrazeneca (7/27/2026)PACCAR (7/28/2026)Ford Motor (7/28/2026)Boeing (7/28/2026)Ecolab (7/28/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
